Garden State Investment Advisory Services LLC Takes $40,000 Position in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX)

Garden State Investment Advisory Services LLC purchased a new position in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned 1.17% of Virpax Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Analyst Ratings Changes

Separately, Maxim Group restated a “hold” rating on shares of Virpax Pharmaceuticals in a research note on Wednesday, October 9th.

Virpax Pharmaceuticals Trading Up 32.9 %

Shares of VRPX stock opened at $0.40 on Friday. The business’s 50 day simple moving average is $0.56 and its 200 day simple moving average is $0.77. Virpax Pharmaceuticals, Inc. has a one year low of $0.29 and a one year high of $5.48.

Virpax Pharmaceuticals Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.